Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.

Academic Article

Published In


  • Cost-effectiveness, HIPEC, Ovarian cancer, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Cost Savings, Cost-Benefit Analysis, Cytoreduction Surgical Procedures, Female, Humans, Hyperthermia, Induced, Models, Economic, Neoadjuvant Therapy, Ovarian Neoplasms, Treatment Outcome
  • Digital Object Identifier (doi)

    Author List

  • Behbakht K; Cohn DE; Straughn JM
  • Start Page

  • 4
  • End Page

  • 5
  • Volume

  • 151
  • Issue

  • 1